1Thompson WG. C. Functional bowel disorders and D. Functionalabdominal pain. In: Drossman DA, Corazziari E, Jalley NJ, eds.Functional gastrointestinal disorders: Rome Ⅱ. 1st ed. Mclean,Virginia: Dgnon and Associates, 2000:360-382.
2Corazza GR, Vaira S, Milletti S, et al. Controlled clinical evaluationof pinsverium bromide and trimebutine in functional disorders of thecolon. Acta Ther, 1983,9:383-389.
3Malysz J, Farraway LA, Christen MO, et al. Pinaverium acts as Ltype calcium channel blocker on smooth muscle of colon. Can JPhysiol Pharmacol, 1997,75:969-975.
4Wittmann T, Feher A, Rosztoczy A, et al. Effectiveness ofpinaverium bromide therapy on colonic motility disorders in irritablebowel syndrome. Orv Hetil, 1999,140: 469-473.
5Galeone M, Stock F, Moise G, et al. Pinaverium bromide versusotilonium bromide in patients with irritable bowel syndrome. CurrThe Res, 1986,39:613-624.
6Froguel E, Chaussade S, Roche H, et al. Effects of an intestinalsmooth muscle calcium channal blocker (pinaverium bromide) oncolonic transit time in humans. J Gastrointest Motil, 1990,2: 176-179.
7Guslandi M. The clinical pharmacological profile of pinaverium bromide. Minerva Med, 1994,85:179-185.
8Fioramonti J, Christen MO, Dupre I, et al. Effect of a selectivecalcium antagonist, pinaverium bromide, on sensitivity to rectal distention in experimental inflammation in rats. Gastroenterology,1997,112(suppl): A731.
